Literature DB >> 9841815

Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients.

J Déchanet1, P Merville, F Bergé, G Bone-Mane, J L Taupin, P Michel, P Joly, M Bonneville, L Potaux, J F Moreau.   

Abstract

In normal persons, circulating gammadelta T cells comprise a minor cell subset (0.5%-6% of total lymphocytes). gammadelta T cells were studied in the context of therapeutic immunosuppression in transplanted patients. Flow cytometry detected an expansion of gammadelta T cells in 31 of 205 renal allograft recipients and in 2 of 41 uremic patients but in none of 45 healthy subjects. Univariate statistical analysis identified cytomegalovirus (CMV) infection (P<. 001), second graft (P<.001), and antithymocyte globulin treatment (P=.01) as three variables associated with high levels (>=6%) of circulating gammadelta T cells in allograft recipients. Multivariate analysis further indicated that CMV infection was the only independent parameter associated with >6% gammadelta T cells. gammadelta T cell expansion directly followed CMV infection and was never observed in persons who did not develop CMV infection. Thus gammadelta T cells may represent a first-line defense mechanism against CMV infection in a person whose alphabeta T cell response has been weakened by immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9841815     DOI: 10.1086/314568

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  The proportion of circulating gammadelta T cells increases after the first week of onset of tularaemia and remains elevated for more than a year.

Authors:  M Kroca; A Tärnvik; A Sjöstedt
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  Tissue distribution, antigen specificity and effector functions of gamma delta T cells in human diseases.

Authors:  G De Libero
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 4.  Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.

Authors:  Ilan Bank; Victoria Marcu-Malina
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

5.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

6.  Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Authors:  Kilian Wistuba-Hamprecht; Alexander Martens; Karin Haehnel; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Anis Larbi; Bastian Schilling; Dirk Schadendorf; Jedd D Wolchok; Christian U Blank; Graham Pawelec; Claus Garbe; Benjamin Weide
Journal:  Eur J Cancer       Date:  2016-07-09       Impact factor: 9.162

7.  Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection.

Authors:  Sarina Ravens; Christian Schultze-Florey; Solaiman Raha; Inga Sandrock; Melanie Drenker; Linda Oberdörfer; Annika Reinhardt; Inga Ravens; Maleen Beck; Robert Geffers; Constantin von Kaisenberg; Michael Heuser; Felicitas Thol; Arnold Ganser; Reinhold Förster; Christian Koenecke; Immo Prinz
Journal:  Nat Immunol       Date:  2017-02-20       Impact factor: 25.606

Review 8.  γδ T cells in tissue physiology and surveillance.

Authors:  Julie C Ribot; Noëlla Lopes; Bruno Silva-Santos
Journal:  Nat Rev Immunol       Date:  2020-10-14       Impact factor: 53.106

Review 9.  Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications.

Authors:  Haishan Li; Suchita Chaudhry; Suchita Chaudry; Bhawna Poonia; Yiming Shao; C David Pauza
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 10.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.